• Press Release

Dolores Malaspina, MD, Appointed Director, Psychosis Program at Icahn School of Medicine at Mount Sinai

  • New York, NY
  • (September 01, 2017)

Dolores Malaspina, MD, MS, MSPH, a renowned psychiatrist, has been named Director of the new Psychosis Program in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai.

An expert clinician with extensive scientific work in psychiatry, Dr. Malaspina will oversee clinical care and jump-start Mount Sinai’s research into the field of psychosis.

“Psychosis is a devastating condition which can be permanently disabling,” said Dr. Malaspina. “The goal of this new program is to identify more at-risk patients and better understand the pathways to psychosis to pinpoint better early interventions.”

Dr. Malaspina joins Mount Sinai from NYU Langone Health where she was the Anita Steckler and Joseph Steckler Professor of Psychiatry and Child Psychiatry as well as founder and Director of the Institute of Social and Psychiatric Initiatives (InSPIRES), a multidisciplinary research program in psychiatry. She also previously served as Chair of   NYU Department of Psychiatry.

Throughout her 30-year career, Dr. Malaspina has made important scientific contributions, including being the first to propose that paternal aging is a predictor of sporadic schizophrenia risk; to demonstrate increased hippocampal activity at rest in schizophrenia; and to demonstrate that olfaction, or the sense of smell, is related to social function in humans. In addition, she has received nearly continuous NIMH funding, including support for epidemiological research in the Jerusalem Perinatal Cohort, psychophysiology studies including olfaction and social function, and work to define specific clinical characteristics and genetic profiles for subtypes of psychosis.

 “Mount Sinai is delighted to have a physician with the expertise of Dr. Malaspina to lead Mount Sinai’s new psychosis program, and expand our clinical services, research, and education,”  said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, and President for Academic Affairs, Mount Sinai Health System. “The recruitment of Dr. Malaspina demonstrates that Mount Sinai will continue to play a national leading role in psychiatry.”

“Under the guidance of Dr. Malaspina, Mount Sinai will work to make the Psychosis Program one of the most successful and prominent in the country,” said Rene S. Kahn, Esther and Joseph Klingenstein Professor of Psychiatry, and Chair, Department of Psychiatry, Icahn School of Medicine at Mount Sinai.

A distinguished educator, Dr. Malaspina has lectured widely and published 300 peer-reviewed papers and scientific chapters. She is the editor of the International Journal of Mental Health and sits on the editorial boards of several journals.

Dr. Malaspina earned her MD, and completed an Internal Medicine internship, at Rutgers New Jersey Medical School. She completed a residency in Psychiatry and a clinical research fellowship at Columbia University Medical Center. Dr. Malaspina holds an MS in Zoology from Rutgers and an MSPH in Epidemiology from Columbia University.


About the Mount Sinai Health System

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2023-2024.

For more information, visit https://www.mountsinai.org or find Mount Sinai on FacebookTwitter and YouTube.